Ambu Forever ForwardShare informationAnnual key figuresQuarterly resultsOwnershipShare CapitalDividend PolicyAnalystsConsensus estimates searchmenu Ambu Forever ForwardclosesearchEndoscopykeyboard_arrow_downcloseSINGLE-USE ENDOSCOPYPulmonologyBronchoscopesVideo LaryngoscopesDisplaying UnitsProductsOfstead webinaraScope 4 Broncho Guys studyProceduresIntubationOne Lung VentilationSecretion ManagementBAL & BWBedside PDTTrainingKnowledgeaScope 5 Broncho benefitsBronchoscopy solution for ICUClinical EvidenceAmbu® aScope™Ear, Nose, Throat (ENT)RhinolaryngoscopesDisplaying UnitsProductsProceduresFlexible laryngoscopyIn-office biopsySwallowing assessmentsKnowledge7 ways for single-useSingle-use rhinolaryngoscope comparisonSimplify bedside swallowing assessmentsClinical EvidenceGastroenterologyDuodenoscopeGastroscopeDisplaying UnitsProductsKnowledge7 key advantages of a large working channelSingle-use gastroscope benefitsClinical insightsAmbu single-use gastroscopesClinical videosTests and evaluationsTestimonialsOne-page clinical case reportsWhite papersAmbu single-use duodenoscopeClinical videosTestimonialsOne-page clinical case reportsWhite papersUrologyCystoscopesUreteroscopesDisplaying UnitsProductsKnowledgeSingle-use cystoscopy benefitsCost-comparison in urologyQualities of effective ureteroscopesNeurologykeyboard_arrow_downclosePatient monitoring and diagnosticsNeurologyEEG ElectrodesEMG ElectrodesEMG Guided InjectionsIntraoperative MonitoringProductsStop cross contaminationClinical EvidenceAmbu® Neuroline EEG CupAmbu® Neuroline EMG NeedlesAmbu® Neuroline Surface ElectrodesKnowledgeNeuroline Cup MRI CT BenefitsSCHEDULE A MEETINGCardiologykeyboard_arrow_downclosePatient monitoring and diagnosticsCardiologyECG ElectrodesProductsClinical EvidenceAmbu® BlueSensor ECG ElectrodesAmbu® WhiteSensor ECG ElectrodesAirway Management & Anaesthesiakeyboard_arrow_downcloseAirway Management and AnaesthesiaBronchoscopesVideo LaryngoscopesDouble Lumen TubesSingle Lumen TubesEndobronchial BlockersLaryngeal MasksFace MasksBreathing BagsResuscitatorsProductsVivaSight-DL Cost EffectivenessDownload summaryClinical EvidenceAmbu® AuraGain™Ambu® Aura-i™Ambu® AuraOnce™Ambu® AuraFlex™Ambu® Aura40™King Vision® Video LaryngoscopeAmbu® VivaSight™ 2 DLTAmbu® VivaSight™ 2 SLTAmbu® Face MasksKnowledgeAnaesthetist workspace studies5 benefits of a connected airway platformEmergency Care & Trainingkeyboard_arrow_downcloseEmergency Care and TrainingResuscitatorsExtrication CollarsVideo LaryngoscopesALS Training ManikinsBLS Training ManikinsProductsTopicsOur iconic Ambu bagClinical EvidenceAmbu® ResuscitatorsAmbu® Military Mark lllAmbu® SPUR® IIAmbu® PEEP ValvesAmbu® ManikinssearchAmbu Forever ForwardSustainabilitykeyboard_arrow_downOur sustainability approachESG PortalInvestorsCareersMediaAboutkeyboard_arrow_downOur CompanyOur historyTop managementOur strategyGlobal Risk and ComplianceReporting and PoliciesNewsContactkeyboard_arrow_downAmbu AddressesLocal DistributorsContact usResearch SupportpublicAmbu GlobalCorporate WebsiteEuropeAmericas and Asia Pacific InvestorsNewskeyboard_arrow_downNews from AmbuSign upReportskeyboard_arrow_downReports in EnglishReports in DanishPresentationskeyboard_arrow_downInvestor presentationsRecent webcastsCapital Markets DaysCalendarShare Infokeyboard_arrow_downShare informationAnnual key figuresQuarterly resultsOwnershipShare CapitalDividend PolicyAnalystsConsensus estimatesGovernancekeyboard_arrow_downCorporate GovernanceAnnual general meetingInvestor Relations PolicyArticles of AssociationTwo share classesTop managementBoard of DirectorsInvestor Relations Contact
InvestorsNewskeyboard_arrow_downNews from AmbuSign upReportskeyboard_arrow_downReports in EnglishReports in DanishPresentationskeyboard_arrow_downInvestor presentationsRecent webcastsCapital Markets DaysCalendarShare Infokeyboard_arrow_downShare informationAnnual key figuresQuarterly resultsOwnershipShare CapitalDividend PolicyAnalystsConsensus estimatesGovernancekeyboard_arrow_downCorporate GovernanceAnnual general meetingInvestor Relations PolicyArticles of AssociationTwo share classesTop managementBoard of DirectorsInvestor Relations ContactConsensus estimatesPre Q4 2025/26 and full year 2025/2622 October 2026
